



SUBJECT INDEX

- Abuse liability, 171
Acoustic startle, 191
Acquisition, 571
Acquisition memory, 321
Active avoidance, 509
Activity, 207
Acute-phase response, 675
Adaptation, 545
ADP-ribosylation, 327
Adrenal gland, 551
Adrenalectomy, 405
Adult behavioral responses, 277
Age, 191
Aggression, 671
Aggressive behavior, 481
Aging, 65, 207, 661
Alcohol, 265, 563, 619
Alcohol consumption, 265
Alcohol drinking, 265
Alcohol-preferring rats, 265
Alfentanil, 351
 α -Melanocyte-stimulating hormone, 339
Ambient temperature, 473
Amnesia, 499
Amphetamine, 41, 345, 601
Analgesia, 17
Angiotensin II, 457
Anogenital distance, 413
Anorexia, 287, 369
Anorexigenic drug, 485
Anticancer response, 399
Anticonflict, 477
Antiestrogen, 55
Antinociception, 421, 587
Anxiety, 277, 375
Anxiolytics, 253
 α_1 -Adrenoceptors, 287
Apomorphine, 1, 83
Ascorbic acid oxidation, 1
Ataxia, 49
Atenolol, 225
 α_2 -Adrenoceptors, 219
Autoreceptors, 83
Aversive conditioning, 661
Barbiturates, 9
Behavior, 1, 115, 453, 473, 539
Behavior genetics, 163
Behavioral, 607
Behavioral activation, 437
Behavioral analysis, 463
Behavioral sensitization, 613
Behavioral toxicology, 97
Benzodiazepines, 171, 253, 345
 β -Adrenoceptors, 241
 β -Adrenoceptor antagonists, 339
Beta-carboline, 551
Bicuculline, 199, 253
Blocking of olfactory cues, 233
Blood pressure, 253, 389
Body temperature, 389, 473
Brain, 321, 421, 457, 491
Brain asymmetry, 359
Brain histamine content, 321
Brain regions, 635
Buprenorphine, 271
Buspirone, 477
Buthionine sulfoximine, 491
C57BL/6J, 163
Ca-antagonist, 509
Caffeine pharmacokinetics, 245
Calcium, 293
Calcium channel blocker, 293
Carassius auratus, 77
Catalepsy, 141, 259, 431
CCK_A agonists, 133
CCK_B agonists, 133
Central nervous system, 219
Central peptide receptors, 463
Central stimulants, 601
CFT, 627
CGP37849, 9
CGP39551, 9
Chicken, 55
Chlordiazepoxide, 107, 345
Choice, 571
Chromium, 607
Chronic treatment, 259, 477
Circadian rhythm, 207
Classical conditioning, 299
Clentiazem, 509
Clonidine, 219
CNS depression, 199
Cocaine, 23, 163, 601, 613, 627
Cocaine abuse, 71
Color and position discrimination, 641
Conditioned position responding, 641
Conditioned preference, 121
Conditioned taste aversion, 299, 675
Conditioned taste avoidance, 299
Conditioning CTL activity, 399
Conscious rats, 219
Convulsion, 49
Corticosterone, 405
Corticostriatal glutamatergic pathways, 1
Crab, 445
Critical periods, 97
Crosstolerance, 9
CY 208-243, 153
Cycloheximide, 499
Cyproheptadine, 383
Cytokines, 141
D₁, 359
D₁ dopamine postsynaptic receptors, 613
D₁ dopamine receptor agonists, 333
D₁ receptor, 153
D₁ receptor binding, 333
D₂ dopamine autoreceptors, 29
D₂ dopamine postsynaptic receptors, 613
D₂ dopamine receptors, 29
D₂ dopamine receptor agonists, 333
D₂ receptor, 153
D₂ receptor binding, 333
d-Amphetamine, 551
DA transporter, 593
DBA/2J, 163
De-nicotinized cigarette, 91
Dehydroevodiamine, 293
Delayed matching to sample, 641
Dentate gyrus, 327
Depression, 147
Desipramine, 481
Development, 491
Diazepam, 665
Differentiation, 641
Dimethylxanthines, 245
Diurnal cycle, 421
Dizocilpine, 305
DL-fenfluramine, 581
DMSO, 521, 527
DNQX, 305
DOI, 309, 545
Dominance, 671
Dominant, 655
Dopamine, 41, 77, 83, 127, 153, 359, 437, 563, 649
Dopamine agonists, 147, 389
Dopamine antagonists, 147
Dopamine metabolism, 83, 333
Dopamine receptors, 35
Dopamine receptor supersensitivity, 23
Dose-response, 539
Down-regulation of β -adrenoceptor, 225
Drug abuse, 171
Drug discrimination, 107, 211, 601
Drug reinforcement, 299, 571
Drug self-administration, 71, 171, 571, 619
DSP-4, 481
DTG, 587
Dyskinesia, 181
Ear-scratch response, 545
ECS, 499

- EEDQ, 127
 Egg laying, 55
 8-OH-DPAT, 375
 Electroconvulsive shock, 241
 Electromyography, 351
 Emotionality, 277
 Emulphor 620, 521, 527
 Estrogen, 55, 369
 Estrous cycle, 369
 Ethanol, 199, 521, 527
 Etonitazene, 571
 Evodiamine, 293
 Exercise, 635
 Exploration, 277
 Exploratory behavior, 375
 Extinction, 437
 Fasting, 405
 Fawn-Hooded rats, 265
 Feeding, 271, 287
 Feeding behavior, 153
 Female, 369, 661
 Fenfluramine, 35
 Fenfluramine, 41, 287
 Fever, 293
 5-HT, 581
 5-HT_{1A} agonists, 375
 5-HT_{1A} receptors, 593
 5-HT₂ receptors, 593
 5-HT_{2A}, 545
 5-HT_{2A} receptors, 309
 5-HT_{2A} receptor binding sites, 383
 5-HT_{2C}, 545
 5,7-Dichlorokynurenic acid, 305
 5,7-Dihydroxytryptamine, 649
 Flavor-association, 121
 Flinders Line rats, 505
 Flupenthixol, 127
 Food anticipation, 207
 Food deprivation, 245
 Food intake, 309, 369, 473, 581
 Food reward, 121
 Forced running, 551
 Frontal cortex, 627
 Functional castration, 55
 Functional model, 219
 GABA, 181
 GABA_A, 593
 Galanin, 655
 γ -Glutamyltranspeptidase, 491
 Gastric emptying, 581
 Gastrin-releasing peptide, 463
 Genes, 619
 Genetic strain, 191
 Gepirone, 477
 Ginseng total saponin (GTS), 23
 Glutamate, 627
 Glutathione, 491, 635
 Glycine, 199, 305
 Goldfish, 77
 Grip strength, 517
 Growth hormone releasing factor, 305
 Gulls, 97, 607
 Habituation, 445
 Haloperidol, 77, 181, 259, 587
 Hamsters, 375
 Head shakes, 309
 Head-twitch response, 545
 Heart, 551
 Heart rate, 253
 Hedonics, 121
 Hereditary epilepsy, 383
 Hippocampus, 551
 Histamine, 321, 421
 Histamine H₃ receptor, 321
 [³H]Ketanserin binding, 309
 Histogramin, 49
 [³H]MK-801 binding, 65
 Holeboard, 277
 Host defense, 675
 Hot plate test, 421
 H₂ receptor, 421
 HPLC, 533
 Humans, 171
 Hunger, 369
 Hyperactivity, 115
 Hypercapnia, 499
 Hypertension, 225
 Hypothalamus, 485
 Hypothermia, 587
 Hypoxia (asphyctic, hemic), 457
 Hypoxia, 533
 IL-1 β , 141
 Imipramine, 147
 Immunotherapy, 399
 In situ hybridization, 655
 In vivo binding, 211
 Inbred mice, 431
 Inbred strains, 17
 Incremental repeated acquisition, 641
 Ingestion, 463
 Inheritance, 661
 Inhibitor of enkephalin degradation, 133
 Insulin, 55
 Interactions between CCK and enkephalins, 133
 Intracranial self-stimulation, 41
 Ipsapirone, 375
 Ischemia, 533
 Isolation, 481
 Isoproterenol, 241
 Jump test, 421
 Kainate, 505
 Ketanserin, 383
 Kidney, 551
 L-Arginine, 327
Larus, 607
 L-BOAA, 445
 Lead, 97
 Learned helplessness, 147
 Learning, 207, 641, 661
 Lever press, 369
 Lick pattern, 121
 Lipopolysaccharide, 675
 Lithium, 299, 345
 L- N^G -Monomethylarginine (L-MeArg), 327
 Locomotion, 49, 277
 Locomotor activity, 9, 133, 163, 333, 389, 521, 527
 Locus coeruleus, 481
 Loss of the righting reflex, 199
 Male rats, 29
 Manganese, 607
 Mefenorex, 485
 Melatonin, 241
 Membrane fluidity, 65
 Memory, 641, 661
 Memory impairment, 509
 Met-enkephalin, 445
 Methcathinone, 601
 Mice, 17, 133, 141, 259, 369, 457, 481, 587, 661
 Microdialysis, 153
 Microstructural analysis, 463
 MK-801, 587
 Monkeys, 641
 Monoamines, 457, 593
 Morphine, 17, 299, 421
 Motivation, 369, 437, 641
 Motor activity, 627
 Motor behavior, 313
 Mouse, 453
 Muscarinic M₁ receptor agonists, 339
 Muscimol, 253
 Muscle dysfunction, 517
 Muscle rigidity, 351
 Mydriasis, 219
 Myoclonus, 533
 Naloxone, 313, 587
 Naltrexone, 277
 Naltrexone by minipump, 413
 NAT, 241
 Neonatal exposure, 115
 Neonatal opioid blockade, 277
 Neostriatum, 431
 Neuron-specific enolase, 491
 Neuropeptide Y, 473
 Nicotine, 191, 233
 Nitric oxide, 265, 369
 Nitric oxide (NO), 327
 Nitric oxide synthase, 265
 Nitrogen excretion, 405
 Nitrous oxide, 351
 NMDA antagonists, 9
 N-Methyl-D-aspartate receptor, 65
 N-Methyl-D-aspartate, 49
 Nociceptive test, 421
 Noradrenaline, 481
 NPA, 127
 NS-3 (CG3703), 499
 Nucleus accumbens, 437, 627
 Obese Zucker rats, 309
 Olfactory bulb, 551
 Olfactory sensation, 233
 Ontogeny, 613
 Open field, 277
 Operant, 271
 Operant behavior, 437, 641
 Opiate receptors, 313
 Opiates, 271, 351
 Opioid, 271, 445, 571
 Opioid plasticity, 277
 Opioid receptors, 35
 Optical isomers, 601
 Oral activity, 649
 Oral drug, 245
 Oral route, 571
 Oxytocin, 339
 Oxytocin receptor antagonists, 339
 Pain sensitivity development, 313
 Palatability, 345
 Paraventricular hypothalamus, 287
 Parietal-cingulate cortex, 627
 Passive avoidance, 321
 Passive avoidance learning, 65
 PDE inhibitors, 211

- Peptide receptor antagonist, 463
 Pergolide, 389
 Phencyclidine, 49
 Phenylpropanolamine, 287
 Physostigmine, 505, 641
 Picrotoxin, 253, 505
 Pigeons, 107
 Pilocarpine, 505
 Pineal gland, 241
 Piribedil, 41
 Place conditioning, 35
 Place preference, 77
 Plasma iron, 675
 Plus-maze, 277, 413
 Postnatal, 97, 607
 Poststroke SHRSP, 509
 Postsynaptic action, 375
 Postsynaptic α_2 -adrenoceptors, 219
 Prazosin, 225
 Pregnancy, 313
 Prenatal cocaine effects, 115
 Prenatal drug effects, 313
 Preweanling rat, 127
 Progesterone, 369, 661
 Progressive ratio, 641
 Propranolol, 225
 Psychopharmacology, 299
 Puffing, 233
 Quaking mutation, 333
 Quinelorane, 389
 Quinpirole, 153, 649
 Rat, 1, 181, 191, 211, 299, 327, 477, 499, 539, 551, 581, 671
 Rat fetus, 359
 Receptor, 545, 649
 Reinforcement, 17, 35, 77, 271, 437, 619
 Repeated testing, 277
 Resting metabolic rate, 55
 Retina, 83
 Reverse tolerance, 23, 259
 Reward, 563, 619
 Rhesus monkeys, 571
 Righting reflex, 665
 Rimcazole, 587
 Ritanserin, 383
 Rolipram, 211
 RS-86, 339
 RTI compounds, 163
 RU486, 405
 Saccharin, 345
 Saccharin preference, 413
 SCH-23390, 153, 259, 359
 Schedule-induced polydipsia, 71, 245
 Scopolamine, 1, 499
 Secondary CTL response, 399
 Seizures, 505
 Self-administration, 563
 Sensitivity, 107
 Sensorimotor reactivity, 191
 Sensory factors, 91
 Sensory gating, 191
 Serine, 199
 Serotonergic agonists, 671
 Serotonin, 41, 287, 485, 533, 649, 671
 Sex differences, 563
 Sexual behavior, 29
 Sexual difference, 613
 σ Receptor, 587
 6-Hydroxydopamine, 649
 Skeletal muscle, 351
 SKF-38393, 359
 Sleep time, 199
 Smoking behavior, 91
 SND 919, 29
 Sodium nitroprusside (SNP), 327
 Spontaneously hypertensive rats, 389
 Stereotypy, 49
 Stimulus control, 71
 Stimulus fading, 571
 Strength, 517
 Stress, 225, 253, 551
 Striatal dopamine turnover, 1
 Striatum, 383, 627
 Strychnine, 199
 Subordinate, 655
 Substance P, 77
 Sulpiride, 153
 Superoxide dismutase, 635
 Supersensitivity, 649
 Tail flick test, 421
 Tail pinch test, 421
 Tail withdrawal, 587
 Tar, 233
 Taste, 233, 345
 Taste aversion, 345
 Taste avoidance, 345
 Taste reactivity, 345
 Temporal, 97
 Temporal response, 641
 Teratogenic, 491
 TGF α , 593
 THC, 141
 Thermoregulation, 293
 Thioperamide, 321
 Threshold, 107
 Thyroxin, 55
 Time course, 539
 Time perception, 641
 TNF α , 141
 TO mice, 9
 Tobacco withdrawal, 91
 Tolerance, 9, 259, 665
 Toxicology, 607
 Training procedures, 107
 Transgenic mice, 593
 Triazolam, 171
 Triiodothyronine, 55
 Tryptophan hydroxylase, 431
 Turning, 389
 Tween-80, 521, 527
 Tween-20, 521, 527
 Two-bottle choice, 563, 619
 Vehicles, 521, 527
 Ventrolateral PAG, 445
 Ventrolateral striatum, 153
 Vestibular nucleus in vitro, 665
 Vigabatrin, 181
 Visible burrow system, 655
 Vulnerability, 563, 619
 Water consumption, 671
 Wheel running, 405
 WIN 35,428, 163, 627
 Yawning, 339, 389
 YC8 lymphoma, 399